Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial.
Davis KL, Fox E, Merchant MS, Reid JM, Kudgus RA, Liu X, Minard CG, Voss S, Berg SL, Weigel BJ, Mackall CL. Davis KL, et al. Among authors: kudgus ra. Lancet Oncol. 2020 Apr;21(4):541-550. doi: 10.1016/S1470-2045(20)30023-1. Epub 2020 Mar 17. Lancet Oncol. 2020. PMID: 32192573 Free PMC article. Clinical Trial.
A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111).
Geller JI, Perentesis JP, Liu X, Minard CG, Kudgus RA, Reid JM, Fox E, Blaney SM, Weigel BJ. Geller JI, et al. Among authors: kudgus ra. Pediatr Blood Cancer. 2017 Nov;64(11):10.1002/pbc.26565. doi: 10.1002/pbc.26565. Epub 2017 Apr 27. Pediatr Blood Cancer. 2017. PMID: 28449393 Free PMC article. Clinical Trial.
A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group.
Chuk MK, Widemann BC, Minard CG, Liu X, Kim A, Bernhardt MB, Kudgus RA, Reid JM, Voss SD, Blaney S, Fox E, Weigel BJ. Chuk MK, et al. Among authors: kudgus ra. Pediatr Blood Cancer. 2018 Aug;65(8):e27077. doi: 10.1002/pbc.27077. Epub 2018 Apr 25. Pediatr Blood Cancer. 2018. PMID: 29693796 Free PMC article. Clinical Trial.
A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315).
Geller JI, Fox E, Turpin BK, Goldstein SL, Liu X, Minard CG, Kudgus RA, Reid JM, Berg SL, Weigel BJ. Geller JI, et al. Among authors: kudgus ra. Cancer. 2018 Dec 1;124(23):4548-4555. doi: 10.1002/cncr.31725. Epub 2018 Nov 5. Cancer. 2018. PMID: 30394521 Free PMC article. Clinical Trial.
Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312).
Cole KA, Pal S, Kudgus RA, Ijaz H, Liu X, Minard CG, Pawel BR, Maris JM, Haas-Kogan DA, Voss SD, Berg SL, Reid JM, Fox E, Weigel BJ. Cole KA, et al. Among authors: kudgus ra. Clin Cancer Res. 2020 Mar 15;26(6):1213-1219. doi: 10.1158/1078-0432.CCR-19-3470. Epub 2019 Dec 19. Clin Cancer Res. 2020. PMID: 31857431 Free PMC article. Clinical Trial.
Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.
DuBois SG, Marachelian A, Fox E, Kudgus RA, Reid JM, Groshen S, Malvar J, Bagatell R, Wagner L, Maris JM, Hawkins R, Courtier J, Lai H, Goodarzian F, Shimada H, Czarnecki S, Tsao-Wei D, Matthay KK, Mosse YP. DuBois SG, et al. Among authors: kudgus ra. J Clin Oncol. 2016 Apr 20;34(12):1368-75. doi: 10.1200/JCO.2015.65.4889. Epub 2016 Feb 16. J Clin Oncol. 2016. PMID: 26884555 Free PMC article. Clinical Trial.
Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma.
DuBois SG, Mosse YP, Fox E, Kudgus RA, Reid JM, McGovern R, Groshen S, Bagatell R, Maris JM, Twist CJ, Goldsmith K, Granger MM, Weiss B, Park JR, Macy ME, Cohn SL, Yanik G, Wagner LM, Hawkins R, Courtier J, Lai H, Goodarzian F, Shimada H, Boucher N, Czarnecki S, Luo C, Tsao-Wei D, Matthay KK, Marachelian A. DuBois SG, et al. Among authors: kudgus ra. Clin Cancer Res. 2018 Dec 15;24(24):6142-6149. doi: 10.1158/1078-0432.CCR-18-1381. Epub 2018 Aug 9. Clin Cancer Res. 2018. PMID: 30093449 Free PMC article. Clinical Trial.
ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study.
Geller JI, Pressey JG, Smith MA, Kudgus RA, Cajaiba M, Reid JM, Hall D, Barkauskas DA, Voss SD, Cho SY, Berg SL, Dome JS, Fox E, Weigel BJ. Geller JI, et al. Among authors: kudgus ra. Cancer. 2020 Dec 15;126(24):5303-5310. doi: 10.1002/cncr.33195. Epub 2020 Sep 11. Cancer. 2020. PMID: 32914879 Free PMC article. Clinical Trial.
24 results